Genentech Seeks Expanded Use of Avastin in Breast Cancer

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 15 No 7
Volume 15
Issue 7

Genentech Seeks Expanded Use of Avastin in Breast Cancer

SAN FRANCISCO, Calif—Genentech has submitted an application to the FDA for expanded use of bevacizumab (Avastin) in combination with taxane chemotherapy for treatment of chemotherapy-naïve recurrent or metastatic breast cancer. Phase III data showed that patients who received bevacizumab in combination with paclitaxel had a 52% reduction in risk of disease progression or death, compared to those who received paclitaxel alone.

Articles in this issue
Surgeons Perform Remote Robotic Animal Nephrectomy Over Public Internet: A First
High-Quality Screening Colonoscopy Priority for GI Docs
Genentech Seeks Expanded Use of Avastin in Breast Cancer
Denosumab Suppresses Bone Resorption in Breast Ca Mets
FDA Approves Priority Review of Merck's Zolinza (Vorinostat)
FDA Approves Revlimid for Myeloma Rx
Real-Time RT Planning, Delivery in the Bronx
Phase III Trial of Enzastaurin for NHL Patients Initiated
Dr. Niederhuber, New Acting Director of NCI, Confronts the Old Problem of an Ever-Declining Institute Budget
Racial Disparities in Prostate Ca Recurrence
HNPCC Pts May Reject Prophylactic Subtotal Colectomy
Improved Colonoscopy Techniques Increase Patient Comfort
New Agents Top Standard Rx in First-Line Advanced RCC
Two Cancer Bills Introduced in the US House of Representatives
Interventions Increase Chemotherapy Center Capacity
Recent Videos
Regardless of disease burden or disease progression speed on front-line therapy, trastuzumab deruxtecan appears effective in HER2-low breast cancer.
Performance status, age, and comorbidities may impact benefit seen with immunotherapy vs chemotherapy in patients with breast cancer.
Related Content
Data from analytical similarity studies and comparative clinical trials support the application of HLX11 in HER2-positive breast cancer.

FDA Accepts BLA for Pertuzumab Biosimilar in HER2+ Breast Cancer

Russ Conroy
February 4th 2025
Article

Data from analytical similarity studies and comparative clinical trials support the application of HLX11 in HER2-positive breast cancer.

Paolo Tarantino, MD, and Matteo Lambertini, MD, PhD discuss findings related to CDK4/6 inhibitors and antibody drug conjugates presented at SABCS 2024.

SABCS 2024 Data Show ‘Great Steps Forward’ in Breast Cancer Care

Paolo Tarantino, MD;Matteo Lambertini, MD
January 13th 2025
Podcast

Paolo Tarantino, MD, and Matteo Lambertini, MD, PhD discuss findings related to CDK4/6 inhibitors and antibody drug conjugates presented at SABCS 2024.

New AI Technology May Have the Potential to Optimize Cancer Surgery

New AI Technology May Have the Potential to Optimize Cancer Surgery

Tim Cortese
February 3rd 2025
Article

Anant Madabhushi, PhD, and Farzad Fereidouni, PhD, are developing the MarginCall technology to reduce time lag and improve tumor margin assessment accuracy in breast and ovarian cancer surgery.

A study evaluating disparities in breast reconstructive surgery sought to assess the impact of culture, race, and ethnicity in minority groups.

Reducing Post-Mastectomy Disparities in Breast Cancer Minority Populations

Rachel A. Greenup, MD, MPH
December 23rd 2024
Podcast

A study evaluating disparities in breast reconstructive surgery sought to assess the impact of culture, race, and ethnicity in minority groups.

Tucatinib plus trastuzumab was well tolerated in patients with metastatic breast cancer and consistent with the combination’s established safety profile.

Tucatinib Combo Shows Meaningful Activity in HER2+ Metastatic Breast Cancer

Roman Fabbricatore
January 30th 2025
Article

Tucatinib plus trastuzumab was well tolerated in patients with metastatic breast cancer and consistent with the combination’s established safety profile.

Inavolisib Combo Meets OS End Point in PIK3CA+ Metastatic Breast Cancer

Inavolisib Combo Meets OS End Point in PIK3CA+ Metastatic Breast Cancer

Tim Cortese
January 28th 2025
Article

The phase 3 INAVO120 trial reported statistically significant OS results in patients with PIK3CA-mutant, locally advanced or metastatic breast cancer.